

Agata Sasor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5407655/publications.pdf>

Version: 2024-02-01

18
papers

601
citations

840776

11
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

1148
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of fibroblast activation protein and the clinicopathological relevance in distal cholangiocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 82-89.	1.5	8
2	Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker. <i>Journal of Translational Medicine</i> , 2020, 18, 343.	4.4	10
3	Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 725-731.	1.5	2
4	YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling. <i>Journal of Translational Medicine</i> , 2020, 18, 77.	4.4	40
5	Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 95-100.	1.5	17
6	Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue. <i>EBioMedicine</i> , 2019, 43, 282-294.	6.1	43
7	Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2019, 17, 29.	1.9	37
8	Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 246-251.	1.5	22
9	Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2018, 18, 1096.	2.6	14
10	Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 9789-9807.	1.8	38
11	The Prognostic Role of Cancer Stem Cell Markers for Long-term Outcome After Resection of Colonic Liver Metastases. <i>Anticancer Research</i> , 2018, 38, 313-320.	1.1	10
12	Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 595-600.	1.5	12
13	Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2017, 17, 810.	2.6	13
14	Pattern of tumour growth of the primary colon cancer predicts long-term outcome after resection of liver metastases. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1233-1238.	1.5	7
15	Pancreatic cancer: yesterday, today and tomorrow. <i>Future Oncology</i> , 2016, 12, 1929-1946.	2.4	286
16	Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 9672-80.	0.5	28
17	Microangiopathy is Common in Submucosal Vessels of the Colon in Patients With Diabetes Mellitus. <i>Review of Diabetic Studies</i> , 2014, 11, 175-180.	1.3	10
18	Analysis of MUC4 expression in human pancreatic cancer xenografts in immunodeficient mice. <i>Anticancer Research</i> , 2014, 34, 3905-10.	1.1	4